Post by Hot Christian Stocks on Apr 29, 2012 7:16:36 GMT -5
TLON - Talon Therapeutics
About Talon Therapeutics
Talon Therapeutics, Inc. is a biopharmaceutical company dedicated to seizing upon medical opportunities, efficiently and expertly leading product candidates through clinical development, and transferring value to patients, patient care providers, shareholders, corporate partners, and employees.
In addition to Marqibo, Talon has additional pipeline opportunities some of which, like Marqibo, have the potential to improve delivery and enhance the therapeutic benefits of well characterized, proven chemotherapies and enable high potency dosing without increased toxicity.
Additional information on Talon Therapeutics can be found at www.talontx.com
Contact Info
2207 Bridgepointe Parkway
Suite 250
San Mateo, CA 94404
Website: www.talontx.com/
Phone: 650-588-6404
Email: info@talontx.com
www.otcmarkets.com/stock/TLON/company-info
Steven R. Deitcher , MD
President & Chief Executive Officer
Steven R. Deitcher, MD, was appointed President and Chief Executive Officer and a member of the Board of Directors for Hana Biosciences, now Talon Therapeutics, in August 2007. Dr. Deitcher originally joined Talon (Hana) as Executive Vice President of Development and Chief Medical Officer in May 2007. Since joining the company, Dr. Deitcher has transformed the organization into a focused, expert, and well-capitalized oncology drug development company. He is responsible for the rapid advancement (acceleration and amplification) of the Marqibo and Menadione Programs in particular. Prior to joining Talon (Hana), Dr. Deitcher served as Vice President, Chief Medical Scientist at Nuvelo where he was responsible for clinical development and medical affairs. Dr. Deitcher has more than 20 years of experience as a academic physician in hematology, medical oncology and clinical thrombosis vascular medicine.
Dr. Deitcher was formerly the head of the section of hematology and coagulation medicine in the department of hematology/oncology and director of research in the department of vascular medicine at The Cleveland Clinic Foundation. While at The Cleveland Clinic, Dr. Deitcher was hematology medical director for the Network for Oncology Communication and Research. Prior to that, he spent four years at The University of Tennessee in positions including associate chairman, department of medicine; director, combined pediatric and adult thrombosis clinic; and director, special and molecular coagulation laboratory.
Dr. Deitcher earned his B.S. and M.D. in the Honors Program in Medical Education at Northwestern University Medical School. He completed his residency in internal medicine at Barnes Hospital and completed his fellowship training in hematology and medical oncology at New England Medical Center and Tufts University School of Medicine. Dr. Deitcher is a member of several medical societies, including The American Society of Hematology, American Society of Clinical Oncology and American Association for Cancer Research, and is a fellow of the Society for Vascular Medicine and Biology. He has published more than 190 peer-reviewed journal papers, abstracts and book chapters.
Marqibo® (vincristine sulfate liposomes injection, OPTISOME™)
A Novel Targeted Nanoparticle-encapsulated Anti-Cancer Compound currently for Acute Lymphoblastic Leukemia (ALL) and Melanoma. Marqibo® has a robust safety database (over 600 patients) and has been extensively evaluated in lymphoid blood cancers such as non-Hodgkin’s lymphoma (NHL) and ALL. Talon has ongoing (or planned) clinical trials which may enable an accelerated approval in 2 indications. Clinical trial development is underway in multiple indications including NHL and melanoma.
Menadione Topical Lotion - A Topical Compound for Skin Rash Associated with EGFR Inhibitors. Treatment with EGFR inhibitors such as Tarceva®, Erbitux® and Vectibix® are associated with an acne-form rash involving the face, neck and upper torso in approximately 75% patients. 50% of patients who manifest skin toxicity experience significant discomfort. This results in drug discontinuation or dose reduction in at least 10% and up to 30% of all subjects. Drug delivery is targeted to the normal location of the EGFR-containing skin cells at the dermal/epidermal junction without interfering with EGFR inhibition systemically at the level of the tumor.
Alocrest™ (vinorelbine liposomes injection, OPTISOME™)
A Novel Targeted Anti-Cancer Compound for Breast and Lung Cancer. Alocrest™ has completed a Phase I dose-escalation trial demonstrating promising anti-cancer activity as well as acceptable and predictable toxicity.
Brakiva™ (topotecan liposomes injection, OPTISOME™)
A Novel Targeted Anti-Cancer Compound for Small-Cell Lung Cancer and Ovarian Cancer. Preclinical data demonstrate the value of Brakiva™ over conventional topotecan.
www.talontx.com/pipeline.php
About Talon Therapeutics
Talon Therapeutics, Inc. is a biopharmaceutical company dedicated to seizing upon medical opportunities, efficiently and expertly leading product candidates through clinical development, and transferring value to patients, patient care providers, shareholders, corporate partners, and employees.
In addition to Marqibo, Talon has additional pipeline opportunities some of which, like Marqibo, have the potential to improve delivery and enhance the therapeutic benefits of well characterized, proven chemotherapies and enable high potency dosing without increased toxicity.
Additional information on Talon Therapeutics can be found at www.talontx.com
Contact Info
2207 Bridgepointe Parkway
Suite 250
San Mateo, CA 94404
Website: www.talontx.com/
Phone: 650-588-6404
Email: info@talontx.com
www.otcmarkets.com/stock/TLON/company-info
Steven R. Deitcher , MD
President & Chief Executive Officer
Steven R. Deitcher, MD, was appointed President and Chief Executive Officer and a member of the Board of Directors for Hana Biosciences, now Talon Therapeutics, in August 2007. Dr. Deitcher originally joined Talon (Hana) as Executive Vice President of Development and Chief Medical Officer in May 2007. Since joining the company, Dr. Deitcher has transformed the organization into a focused, expert, and well-capitalized oncology drug development company. He is responsible for the rapid advancement (acceleration and amplification) of the Marqibo and Menadione Programs in particular. Prior to joining Talon (Hana), Dr. Deitcher served as Vice President, Chief Medical Scientist at Nuvelo where he was responsible for clinical development and medical affairs. Dr. Deitcher has more than 20 years of experience as a academic physician in hematology, medical oncology and clinical thrombosis vascular medicine.
Dr. Deitcher was formerly the head of the section of hematology and coagulation medicine in the department of hematology/oncology and director of research in the department of vascular medicine at The Cleveland Clinic Foundation. While at The Cleveland Clinic, Dr. Deitcher was hematology medical director for the Network for Oncology Communication and Research. Prior to that, he spent four years at The University of Tennessee in positions including associate chairman, department of medicine; director, combined pediatric and adult thrombosis clinic; and director, special and molecular coagulation laboratory.
Dr. Deitcher earned his B.S. and M.D. in the Honors Program in Medical Education at Northwestern University Medical School. He completed his residency in internal medicine at Barnes Hospital and completed his fellowship training in hematology and medical oncology at New England Medical Center and Tufts University School of Medicine. Dr. Deitcher is a member of several medical societies, including The American Society of Hematology, American Society of Clinical Oncology and American Association for Cancer Research, and is a fellow of the Society for Vascular Medicine and Biology. He has published more than 190 peer-reviewed journal papers, abstracts and book chapters.
Marqibo® (vincristine sulfate liposomes injection, OPTISOME™)
A Novel Targeted Nanoparticle-encapsulated Anti-Cancer Compound currently for Acute Lymphoblastic Leukemia (ALL) and Melanoma. Marqibo® has a robust safety database (over 600 patients) and has been extensively evaluated in lymphoid blood cancers such as non-Hodgkin’s lymphoma (NHL) and ALL. Talon has ongoing (or planned) clinical trials which may enable an accelerated approval in 2 indications. Clinical trial development is underway in multiple indications including NHL and melanoma.
Menadione Topical Lotion - A Topical Compound for Skin Rash Associated with EGFR Inhibitors. Treatment with EGFR inhibitors such as Tarceva®, Erbitux® and Vectibix® are associated with an acne-form rash involving the face, neck and upper torso in approximately 75% patients. 50% of patients who manifest skin toxicity experience significant discomfort. This results in drug discontinuation or dose reduction in at least 10% and up to 30% of all subjects. Drug delivery is targeted to the normal location of the EGFR-containing skin cells at the dermal/epidermal junction without interfering with EGFR inhibition systemically at the level of the tumor.
Alocrest™ (vinorelbine liposomes injection, OPTISOME™)
A Novel Targeted Anti-Cancer Compound for Breast and Lung Cancer. Alocrest™ has completed a Phase I dose-escalation trial demonstrating promising anti-cancer activity as well as acceptable and predictable toxicity.
Brakiva™ (topotecan liposomes injection, OPTISOME™)
A Novel Targeted Anti-Cancer Compound for Small-Cell Lung Cancer and Ovarian Cancer. Preclinical data demonstrate the value of Brakiva™ over conventional topotecan.
www.talontx.com/pipeline.php